NCT06151535View on ClinicalTrials.gov

A Study to Evaluate the Safety and Effectiveness of ELAPR002f Injectable Gel for the Improvement of Skin Quality in Adult Participants

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 19, 2023

Primary Completion Date

February 24, 2025

Study Completion Date

February 24, 2025

Conditions
Skin Quality Deficit
Interventions
DEVICE

ELAPR002f Injectable Gel

Intradermal Injections

Trial Locations (1)

37134

CRC - Centro Ricerche Cliniche di Verona S.r.l. /ID# 226370, Verona

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY